Form 4: Corcept Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 17,493 Common Stock at $8.27 ($144,667) on September 17, 2026; holds 31,156 after (Direct).
- Option exercise/conversion: disposed of 17,493 Stock option (right to buy) on September 17, 2026; holds 182,507 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Gary Charles Robb — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 17,493 | $8 | $144.7K | 31,156 |
| 2026-09-17 | Option exercise/conversion | Stock option (right to buy) | 17,493 | — | — | 182,507 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (17,493 shares) |
| 2026-09-17 | Option exercise/conversion (17,493 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, neutral, Gary Charles Robb
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.